We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitelumiracapital.com
Phone416-213-4223
Employees
DescriptionVenture Capital Firm

Funds

Total$150M
Lumira Capital ll, 3/2012 $100M
Merck Lumira Biosciences Fund, 3/2012 $50M
Lumira Capital II, 11/2013 C$10M

Offices

HQ
141 Adelaide Street West, Suite 770
ON
Toronto, M5H 3L5, CAN
Waltham, USA
303 Wyman St., Suite 300
Waltham, MA, 02451-1208
USA
Montreal, CAN
3400 De Maisonneuve Ouest, Suite 1050
Quebec
Montreal, H3Z 3B8, CAN

People

Managing General Partner
Managing Director
Managing Director
Managing Director
Managing Director
VP Finance
Principal
Senior Associate

Tags

Lumira Capital

Built on a foundation that leverages over 20 years of North American venture capital experience, the Lumira Capital team has substantial experience helping to build transformational health and life science companies.

Our goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.

As partners in our businesses we are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.

Recent Milestones

Investments

Company Date Round Size Participants
Cardiac Dimensions 4/2014Venture Round$20M1
Aurinia Pharmaceuticals 2/2014Post IPO Equity$52M9
enGene 8/2013Series B$13.3M1
DC Devices 3/2013Series A$10.7M3
BAROnova 2/2013Series C$27.3M6
Thrasos 10/2012Series C$35M7
U-Systems 6/2012Private Equity$5M3
Argos Therapeutics 4/2012Series D$25M5
U-Systems 5/2011Venture Round$6.5M4

Videos

Sources

  1. Teralys Capital invests in two new Lumira Capital life sciences funds (newswire.ca) [edit]
  2. Teralys Capital invests in two new Lumira Capital life sciences funds (newswire.ca) [edit]
  3. Lumira Capital Receives C$10M Commitment for Fund II (pevc.dowjones.com) [edit]
  4. Amgen to Acquire Privately Held KAI Pharmaceuticals (prnewswire.com) [edit]
  5. Cardiac Dimensions Completes $20M Financing (finsmes.com) [edit]
  6. Aurinia Announces US$52 Million Private Placement (auriniapharma.com) [edit]
  7. enGene raises $13.25m financing (finsmes.com) [edit]
  8. SEC (sec.gov) [edit]
  9. BAROnova® Secures $27.3M Investment To Fund Clinical Trial For Weight-loss Device (prnewswire.com) [edit]
  10. Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program for Treatment of Acute Kidney Injury (businesswire.com) [edit]
  11. SEC (sec.gov) [edit]
  12. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012 (argostherapeutics.com) [edit]
  13. U-Systems raises $6.5M new funding (bizjournals.com) [edit]
Edit This Page
Last Edited 4/16/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy